Skip to main content

Table 2 M2 vaccine expressing MC38 neoantigens (see Fig. 3)

From: Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth

   WT Peptide Neoantigen   
# Symbol Seq H2-Db H2-Kb Seq H2-Db H2-Kb DAI Imm. Resp.
11 Tmem135 FALMNRKAL 12 1426 FALMNLKAL 12 681 < 5 +
12 Aatf MAPIDHTAM 297 5239 MAPIDHTTM 90 6675 > 5
13 Spire1 SAIRSYQDV 814 271 SAIRSYQYV 28 43 > 5 +
14 Zbtb40 KSFHFYCRL 7827 4 KSFHFYCPL 1318 4 < 5
15 Slc12a4 LSAARYALL 26,865 16 LSASRYALL 27,697 14 < 5
16 Nfe2l2 ASYSQVAHI 4627 66 ASYSLVAHI 1309 23 < 5
17 Herc6 CGYEHTAVL 7636 140 CVYEHTAVL 9017 91 < 5
18 Copb2 MSYFLQGKL 6858 72 MSYFLQGTL 2039 51 < 5
19 Reps1 AQLPNDVVL 89 9261 AQLANDVVL 16 8591 > 5 +
20 Adpgk ASMTNRELM 6 2267 ASMTNMELM 4 1288 < 5 +
  1. Predicted binding affinity by NetMHC-4 software. Immunogenic neoantigens (+) are indicated. Mutated residues are in bold